Skip To Main Content
Adhikaar Marwaha on Muck Rack

Adhikaar Marwaha

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adhikaar

Contact Adhikaar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching

|
By Adhikaar Marwaha, AJ Venkatakrishnan, Karthik Murugadoss
| preprints.org
You are already at the latest version Alopecia is an emerging concern during tirzepatide or semaglutide therapy for weight management, but whether it is a consequence of weight loss or reflects incretin-specific biology remains unclear. Here we conduct an observational study comparing new users of tirzepatide (Zepbound, Mounjaro) or semaglutide (Wegovy, Ozempic, Rybelsus) with at least two prescriptions, no documented alopecia prior to the first prescription, and complete 12-month follow-up.
Open in Who Shared Issue with article?

Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age Patients

|
By AJ Venkatakrishnan, Adhikaar Marwaha, Avinash Aman
| preprints.org
You are already at the latest version The U.S. Medicare GLP-1 Bridge program and existing Part D pathways are expanding access to tirzepatide therapy for older adults, including Zepbound through the Bridge for weight management and Mounjaro through Part D coverage for type 2 diabetes. This necessitates identification of clinical vulnerabilities in geriatric patients that may emerge during pharmacologic weight loss.
Open in Who Shared Issue with article?
See all 2 articles